問卷

TPIDB > Search Result

Search Result

篩選

List

20Cases

2025-11-01 - 2033-12-31

Phase III

Not yet recruiting
A phase III, open-label, randomized, multicenter, parallel-group trial evaluating the efficacy and safety of first-line trastuzumab deruxtecan combined with rilvegostomig or volrustomig versus pembrolizumab plus chemotherapy in locally advanced, unresectable, or metastatic HER2-overexpressing non-squamous NSCLC (DESTINY-Lung07).
  • Condition/Disease

    Locally advanced unresectable or metastatic HER2-overexpressing non-squamous non-small cell lung cancer

  • Test Drug

    Trastuzumab Deruxtecan(AZD4552 DS-8201A)

Participate Sites
9Sites

Recruiting9Sites

2025-02-19 - 2029-05-04

Phase IV

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2026-03-16 - 2031-11-30

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-01-01 - 2032-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting1Sites

2026-03-16 - 2029-01-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting2Sites

Recruiting10Sites

2022-01-01 - 2031-02-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2022-02-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-09-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2022-01-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2022-09-15 - 2026-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2